Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 3,301–3,400 of 10,906
Association of Facial Pustular Neutrophilic Eruption With Messenger RNA–1273 SARS-CoV-2 Vaccine
Merrill, E. D., Kashem, S. W., Amerson, E. H., et al. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.2474 · Cited by 21
van der Heiden, M., Shetty, S. A., Bijvank, E., Beckers, L., Çevirgel, A., van Sleen, Y., Tcherniaeva, I., Ollinger, T., Burny, W., van Binnendijk, R. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50760-9 · Cited by 23
Targeting the Inside of Cells with Biologicals: Chemicals as a Delivery Strategy
Marschall, A. L. J. (2021) · BioDrugs · doi:10.1007/s40259-021-00500-y · Cited by 22
Efficacy and Safety of Vaccinations in Geriatric Patients: A Literature Review
Ciarambino, T., Crispino, P., Buono, P., Giordano, V., Trama, U., Iodice, V., Leoncini, L., & Giordano, M. (2023) · Vaccines · doi:10.3390/vaccines11091412 · Cited by 25
Lewis, N. M., Naioti, E. A., Self, W. H., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A. E., Gaglani, M., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab619 · Cited by 22
New Omicron-specific vaccines offer similar protection to existing boosters
Callaway, E. (2022) · Nature · doi:10.1038/d41586-022-02806-5 · Cited by 21
Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2
Stoddard, M., Sarkar, S., Lin, Y., Nolan, R. P., White, D. E., White, L. F., Hochberg, N. S., & Chakravarty, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254734 · Cited by 22
Minkner, R., Boonyakida, J., Park, E. Y., & Wätzig, H. (2022) · Electrophoresis · doi:10.1002/elps.202200079 · Cited by 23
McCollum, C. R., Courtney, C. M., O’Connor, N. J., Aunins, T. R., Ding, Y., Jordan, T. X., Rogers, K. L., Brindley, S. M., Brown, J. M., Nagpal, P., et al. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00510 · Cited by 18
NK cells in COVID-19—from disease to vaccination
Hammer, Q., Cuapio, A., Bister, J., Björkström, N. K., & Ljunggren, H. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad031 · Cited by 28
Structure-Based and Rational Design of a Hepatitis C Virus Vaccine
Guest, J. D., & Pierce, B. G. (2021) · Viruses · doi:10.3390/v13050837 · Cited by 21
Noori, M., Azizi, S., Varaki, F. A., Nejadghaderi, S. A., & Bashash, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109046 · Cited by 23
mRNA Technology and Mucosal Immunization
Toniolo, A., Maccari, G., & Camussi, G. (2024) · Vaccines · doi:10.3390/vaccines12060670 · Cited by 24
COVID-19 Compulsory Vaccination: Legal and Bioethical Controversies
Gibelli, F., Ricci, G., Sirignano, A., & Leo, D. D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.821522 · Cited by 28
Blake, T. R., Haabeth, O. A. W., Sallets, A., McClellan, R. L., Castillo, T. J. D., Vilches-Moure, J. G., Ho, W. C., Wender, P. A., Levy, R., & Waymouth, R. M. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00019 · Cited by 23
Tursi, N. J., Tiwari, S., Bedanova, N. M., Kannan, T., Parzych, E. M., Okba, N. M. A., Liaw, K., Sárközy, A., Livingston, C., Trullen, M. I., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102035 · Cited by 40
Mahalingam, G., Rachamalla, H. K., Arjunan, P., Karuppusamy, K. V., Periyasami, Y., Mohan, A., Subramaniyam, K., Salma, M., Rajendran, V., Moorthy, M., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.028 · Cited by 23
Challenges and opportunities in the development of mucosal mRNA vaccines
Kirtane, A. R., Tang, C., Freitas, D., Bernstock, J. D., & Traverso, G. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102388 · Cited by 27
Sonoda, J., Mizoguchi, I., Inoué, S., Watanabe, A., Sekine, A., Yamagishi, M., Miyakawa, S., Yamaguchi, N., Horio, E., Katahira, Y., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109094 · Cited by 24
Toida, R., Uezono, S., Komatsu, H., et al. (2021) · CEN Case Reports · doi:10.1007/s13730-021-00657-z · Cited by 21
The relationship between COVID-19 vaccines and increased blood pressure: A word of caution
Buso, G., Rosei, C. A., & Muiesan, M. L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.03.002 · Cited by 25
Wei, J., Matthews, P. C., Stoesser, N. E., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., Farrar, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31495-x · Cited by 26
COVID-19 and the liver: What do we know so far?
Nasa, P., & Alexander, G. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i5.522 · Cited by 23
Microfluidics for Nanomedicine Delivery
Chen, K., Yang, H., & Cai, R. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c02052 · Cited by 26
Burn, E., Roel, E., Pistillo, A., Fernández‐Bertolín, S., Aragón, M., Raventós, B., Reyes, C., Verhamme, K. M. C., Rijnbeek, P. R., Li, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34669-9 · Cited by 26
Debunking mRNA Vaccine Misconceptions—An Overview for Medical Professionals
Hitti, F. L., & Weissman, D. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.02.004 · Cited by 21
Tang, K., Wei, Z., & Wu, X. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27956 · Cited by 20
Effects of Varicella-Zoster Virus Glycoprotein E Carboxyl-Terminal Mutation on mRNA Vaccine Efficacy
Cao, H., Wang, Y., Luan, N., Lin, K., & Liu, C. (2021) · Vaccines · doi:10.3390/vaccines9121440 · Cited by 25
Influenza Virus and SARS-CoV-2 Vaccines
Sandor, A., Sturdivant, M. S., & Ting, J. P. ‐. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001287 · Cited by 23
Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy
Damavandi, A. R., Dowran, R., Sharif, S. A., Kashanchi, F., & Jafari, R. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00729-6 · Cited by 23
Mohamed, Y., El‐Maradny, Y. A., Saleh, A. K., Nayl, A. A., El‐Gendi, H., & El‐Fakharany, E. M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113499 · Cited by 23
Gori, D., Reno, C., Remondini, D., Durazzi, F., & Fantini, M. P. (2021) · Vaccines · doi:10.3390/vaccines9020173 · Cited by 22
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02663-z · Cited by 25
Assessing the risk of vaccine-driven virulence evolution in SARS-CoV-2
Miller, I. F., & Metcalf, C. J. E. (2022) · Royal Society Open Science · doi:10.1098/rsos.211021 · Cited by 23
Pereson, M. J., Amaya, L., Neukam, K., Baré, P., Echegoyen, N., Badano, M. N., Lucero, A., Martelli, A., Garcia, G. H., Videla, C. M., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.05.009 · Cited by 19
Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction
Hoff, N., Freise, N. F., Schmidt, A. G., Firouzi-Memarpuri, P., REIFENBERGER, J., Luedde, T., Bölke, E., Meller, S., Homey, B., Feldt, T., et al. (2021) · European journal of medical research · doi:10.1186/s40001-021-00557-z · Cited by 19
mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic
Xu, Z., & Fisher, D. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155728 · Cited by 29
Neuro-Ophthalmological Complications of the COVID-19 Vaccines: A Systematic Review
Lotan, I., Lydston, M., & Levy, M. (2022) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001537 · Cited by 22
Tong, R., Luo, L., Zhao, Y., Sun, M., Li, R., Zhong, J., Chen, Y., Hu, L., Li, Z., Shi, J., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2187245 · Cited by 21
“CorV [2,3] and CoronaVac [4], mRNA vaccines BNT162b2 [5] and mRNA-1273 [6], adenovirus vaccines AZD1222 [7] and Ad5-nCoV [8], and protein”
BackgroundHaydu, J. E., Maron, J. S., Redd, R. A., Gallagher, K., Fischinger, S., Barnes, J. A., Hochberg, E. P., Johnson, P. C., Takvorian, R. W., Katsis, K., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006627 · Cited by 22
Yassini, P., Hutchens, M., Paila, Y. D., Schoch, L., Aunins, A., Siangphoe, U., & Paris, R. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2190690 · Cited by 22
Coarse-Grained Simulation of mRNA-Loaded Lipid Nanoparticle Self-Assembly
Grzetic, D. J., Hamilton, N. B., & Shelley, J. C. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00216 · Cited by 27
Kitagawa, Y., Imai, K., Matsuoka, M., Fukada, A., Kubota, K., Sato, M., Takada, T., Noguchi, S., Tarumoto, N., Maesaki, S., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27338 · Cited by 18
Artificial Intelligence in battling infectious diseases: A transformative role
Li, C., Ye, G., Jiang, Y., Wang, Z., Yu, H., & Yang, M. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29355 · Cited by 26
Verstegen, N. J. M., Hagen, R. R., van den Dijssel, J., Kuijper, L. H., Kreher, C., Ashhurst, T. M., Kummer, L. Y. L., Steenhuis, M., Duurland, M. C., de Jongh, R., et al. (2022) · eLife · doi:10.7554/elife.77969 · Cited by 21
Charilaou, P., Tricarico, C. J., Battat, R. J., Scherl, E., Longman, R., & Lukin, D. J. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.007 · Cited by 21
Jayagobi, P. A., Ong, C., Yeo, K. T., Lim, C. C., Seet, M. J., Kwek, L. K., Ku, C. W., Chan, J. K. Y., Mathur, M., & Chien, C. M. (2021) · medRxiv · doi:10.1101/2021.06.29.21259741 · Cited by 21
What should define a SARS-CoV-2 “breakthrough” infection?
Schieffelin, J. S., Norton, E. B., & Kolls, J. K. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151186 · Cited by 22
Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge
Baden, L. R., El Sahly, H. M., Essink, B., Follmann, D., Neuzil, K. M., August, A., Clouting, H., Fortier, G., Deng, W., Han, S., et al. (2021) · medRxiv · doi:10.1101/2021.09.17.21263624 · Cited by 21
Self-citationBall, J., Bradley, A., Le, A., Tisdale, J. F., & Uchida, N. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.016 · Cited by 31
Hypertension and COVID-19: Updates from the era of vaccines and variants
Swamy, S., Koch, C. A., Hannah‐Shmouni, F., Schiffrin, E. L., Kłubo-Gwieździńska, J., & Gubbi, S. (2021) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2021.100285 · Cited by 27
Wussow, F., Kha, M., Kim, T. H., Ly, M., Yll, M., Kar, S., Lewis, M. G., Chiuppesi, F., & Diamond, D. J. (2023) · npj Vaccines · doi:10.1038/s41541-023-00640-y · Cited by 23
Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections
Suleyman, G., Fadel, R. A., Brar, I., Kassab, R., Khansa, R., Sturla, N., Alsaadi, A., Latack, K. A., Miller, J. B., Tibbetts, R. J., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac116 · Cited by 26
Self-citationEfficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
(2021) · doi:10.1101/2021.05.13.21256639 · Cited by 1,085
Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272
Bozzi, G., Lombardi, A., Ludovisi, S., Muscatello, A., Manganaro, L., Cattaneo, D., Gori, A., & Bandera, A. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.10.021 · Cited by 21
Single intramuscular injection of self-amplifying RNA of Nppa to treat myocardial infarction
Zhang, K., Tao, H., Zhu, D., Yue, Z., Hu, S., Wu, Y., Yan, N., Hu, Y., Liu, S., Liu, M., et al. (2026) · Science · doi:10.1126/science.adu9394 · Cited by 34
Aksyuk, A. A., Bansal, H., Wilkins, D. E., Stanley, A. M., Sproule, S., Maaske, J., Sanikommui, S., Hartman, W. R., Sobieszczyk, M. E., Falsey, A. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100882 · Cited by 25
Sanz‐Leon, P., Hamilton, L. H. W., Raison, S. J., Pan, A. J. X., Stevenson, N. J., Stuart, R. M., Abeysuriya, R., Kerr, C. C., Lambert, S. B., & Roberts, J. A. (2022) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2021.0311 · Cited by 19
Toll-like Receptors in Viral Encephalitis
Gern, O. L., Mulenge, F., Pavlou, A., Ghita, L., Steffen, I., Stangel, M., & Kalinke, U. (2021) · Viruses · doi:10.3390/v13102065 · Cited by 26
Retinal vascular occlusion and SARS-CoV-2 vaccination
Vujosevic, S., Limoli, C., Romano, S., Vitale, L., Villani, E., & Nucci, P. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05707-5 · Cited by 22
Gómez, C. E., Perdiguero, B., Usero, L., Marcos-Villar, L., Miralles, L., Leal, L., Sorzano, C. Ó. S., Sánchez-Corzo, C., Plana, M., García, F., et al. (2021) · Vaccines · doi:10.3390/vaccines9090959 · Cited by 21
Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants
(2021) · doi:10.1101/2021.09.29.21264199 · Cited by 230
Villanueva, P., Wadia, U. D., Crawford, N. W., Messina, N. L., Kollmann, T. R., Lucas, M., Manning, L. A., Richmond, P., Pittet, L. F., & Curtis, N. C. (2022) · npj Vaccines · doi:10.1038/s41541-021-00421-5 · Cited by 22
Bell’s palsy following COVID-19 vaccination with high CSF antibody response
Obermann, M., Krasniqi, M., Ewers, N., Fayad, J., & Haeberle, U. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05496-5 · Cited by 25
COVID-19 vaccination among Spanish nephrologists: Acceptance and side effects
Quiroga, B., Sánchez-Álvarez, E., Goicoechea, M., & de Sequera, P. (2021) · Journal of Healthcare Quality Research · doi:10.1016/j.jhqr.2021.05.002 · Cited by 22
Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters
Kulkarni, R., Chen, W.-C., Lee, Y., Kao, C., Hu, S.-L., Ma, H., Jan, J., Liao, C., Liang, J., Ko, H., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257191 · Cited by 21
Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?
Hromić‐Jahjefendić, A., Barh, D., Uversky, V. N., Aljabali, A. A. A., Tambuwala, M. M., Alzahrani, K. J., Alzahrani, F. M., Alshammeri, S., & Lundstrom, K. H. (2023) · Vaccines · doi:10.3390/vaccines11020208 · Cited by 23
COVID-19 Vaccines in Patients With Chronic Liver Disease
Sharma, A., Patnaik, I., Kumar, A. S., & Gupta, R. K. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.06.013 · Cited by 21
Characteristics and outcomes of adverse events after COVID‐19 vaccination
Kewan, T. Z., Flores, M., Mushtaq, K., Alwakeel, M. I., Burton, R., Campbell, J., Perry, H., Al‐Jaghbeer, M. J., & Fadel, F. A. (2021) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12565 · Cited by 20
Hill, E. M., & Keeling, M. J. (2021) · Journal of The Royal Society Interface · doi:10.1098/rsif.2021.0214 · Cited by 22
Kerr, S., Bedston, S., Bradley, D., Joy, M., Lowthian, E., Mulholland, R., Akbari, A., Hobbs, R. F., Katikireddi, S. V., de Lusignan, S., et al. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac199 · Cited by 24
Cravedi, P., Ahearn, P. C., Wang, L., Yalamarti, T., Hartzell, S., Azzi, Y., Menon, M. C., Jain, A. V., Billah, M., Fernández-Viña, M., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021040573 · Cited by 25
Optimizing global COVID-19 vaccine allocation: An agent-based computational model of 148 countries
Li, Q., & Huang, Y. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010463 · Cited by 19
Iavarone, M. A., Tosetti, G., Facchetti, F., Topa, M., Lim, J. M. E., Hang, S. K., Licari, D., Lombardi, A., D’Ambrosio, R., Degasperi, E., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.09.010 · Cited by 20
Stewart, E. L., Counoupas, C., Johansen, M. D., Nguyen, D. H., Miemczyk, S., Hansbro, N. G., Ferrell, K. C., Ashhurst, A. S., Alca, S., Ashley, C. L., et al. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00578-9 · Cited by 26
Short, K. K., Lathrop, S. K., Davison, C. J., Partlow, H. A., Kaiser, J. A., Tee, R. D., Lorentz, E. B., Evans, J. T., & Burkhart, D. J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071455 · Cited by 25
The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2
Jamous, Y. F., & Alhomoud, D. A. (2023) · Cureus · doi:10.7759/cureus.45602 · Cited by 36
Fernandes, A., Chaudhari, S., Jamil, N., & Gopalakrishnan, G. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.01.013 · Cited by 22
Magen, E., Mukherjee, S., Bhattacharya, M., Detroja, R., Merzon, E., Blum, I., Livoff, A., Shlapobersky, M., Baum, G., Talisman, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10071135 · Cited by 24
Early approval of COVID-19 vaccines: Pros and cons
Rahman, M. A., & Islam, M. S. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1944742 · Cited by 25
Septic Arthritis of the Shoulder After SARS-CoV-2 Pfizer Vaccination
Massel, D. H., Haziza, S., Rivera, S., Mohile, N. V., Subhawong, T. K., & Hernandez, V. H. (2021) · JBJS Case Connector · doi:10.2106/jbjs.cc.21.00090 · Cited by 21
Nicolas, A., Sannier, G., Dubé, M., Nayrac, M., Tauzin, A., Painter, M. M., Goel, R. R., Laporte, M., Gendron‐Lepage, G., Medjahed, H., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105904 · Cited by 23
Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination
Fryer, H. A., Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Biochemical Society Transactions · doi:10.1042/bst20220415 · Cited by 19
Tissue immunity to SARS‐CoV‐2: Role in protection and immunopathology*
Rybkina, K., Davis‐Porada, J., & Färber, D. L. (2022) · Immunological Reviews · doi:10.1111/imr.13112 · Cited by 20
Side effects of messenger RNA vaccines and prior history of COVID-19, a cross-sectional study
Kadali, R. A. K., Janagama, R., Yedlapati, S. H., Kanike, N., Gajula, V., Madathala, R. R., Poddar, S., Sukka, N., Jogu, H. R., Racherla, S., et al. (2021) · American Journal of Infection Control · doi:10.1016/j.ajic.2021.10.017 · Cited by 20
Infection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting
Townsend, J. P., Hassler, H. B., & Dornburg, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28461 · Cited by 25
Elliott, T., Cheeseman, H. M., Evans, A. B., Day, S., McFarlane, L. R., O’Hara, J., Kalyan, M., Amini, F., Cole, T., Winston, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010885 · Cited by 22
HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development
Shepherd, B. L. O., Chang, D., Vasan, S., Ake, J. A., & Modjarrad, K. (2022) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00597-4 · Cited by 21
Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine
Ndzouboukou, J. B., Zhang, Y., Lei, Q., Lin, X., Yao, Z., Fu, H., Yuan, L., & Fan, X. (2021) · Current Medical Science · doi:10.1007/s11596-021-2461-8 · Cited by 22
Diagnostic performance of a novel antigen-capture ELISA for the detection of SARS-CoV-2
Yadegari, H., Mohammadi, M., Maghsood, F., Vanan, A. G., Bahadori, T., Golsaz‐Shirazi, F., Zarnani, A., Salimi, V., Jeddi‐Tehrani, M., Amiri, M. M., et al. (2023) · Analytical Biochemistry · doi:10.1016/j.ab.2023.115079 · Cited by 21
Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell immunoprofiling
Schreibing, F., Hannani, M. T., Kim, H., Nagai, J. S., Ticconi, F., Fewings, E., Bleckwehl, T., Begemann, M., Torow, N., Kuppe, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1066176 · Cited by 24
Lécuyer, D., Nardacci, R., Tannous, D., Gutierrez-Mateyron, E., Nathan, A. D., Subra, F., Primio, C. D., Quaranta, P., Petit, V., Richetta, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1270081 · Cited by 22
Abdul‐Mutakabbir, J. C., Granillo, C., Peteet, B. J., Dubov, A., Montgomery, S., Hutchinson, J., Casey, S. J., Simmons, K., Fajardo, A., & Belliard, J. C. (2022) · Vaccines · doi:10.3390/vaccines10081364 · Cited by 20
Safety, Immunogenicity, and Mechanism of a Rotavirus mRNA-LNP Vaccine in Mice
Lu, C., Li, Y., Chen, R., Hu, X., Leng, Q., Song, X., Lin, X., Ye, J., Wang, J., Li, J., et al. (2024) · Viruses · doi:10.3390/v16020211 · Cited by 20
Nordström, P., Ballin, M., & Nordström, A. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5814 · Cited by 22
Abu‐Rumeileh, S., Mayer, B., Still, V., Tumani, H., Otto, M., & Şenel, M. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10849-3 · Cited by 20
Anti-RBD IgA and IgG Response and Transmission in Breast Milk of Anti-SARS-CoV-2 Vaccinated Mothers
Trofin, F., Năstase, E. V., Iancu, L. S., Constantinescu, D., Cianga, C. M., Luncă, C., Ursu, R. G., Cianga, P., & Dorneanu, O. (2022) · Pathogens · doi:10.3390/pathogens11030286 · Cited by 22
The need for a global COVID-19 maternal immunisation research plan
Bardají, A., Sevene, E., Cutland, C., Menéndez, C., Omer, S. B., Aguado, T., & Muñoz, F. M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00146-x · Cited by 20
Melton, A., Doyle‐Meyers, L. A., Blair, R. V., Midkiff, C. C., Melton, H. J., Russell‐Lodrigue, K., Aye, P. P., Schiro, F. R., Fahlberg, M. D., Szeltner, D. M., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010162 · Cited by 21
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.